NCT07537751Completed
Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis
Comparative Study Between Topical Crisaborole 2% and Topical Fluticasone Propionate 0.05% in Treatment of Patients With Mild to Moderate Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
This randomized, double-blind trial compared topical crisaborole 2% with topical fluticasone propionate 0.05% in children aged 1-12 years with mild to moderate atopic dermatitis. Forty patients were assigned to receive either crisaborole or fluticasone twice daily on affected areas for 6 weeks, with responders (\>75% improvement in SCORAD) continuing the same treatment twice weekly for 12 weeks as maintenance. The study evaluated improvement in disease severity using SCORAD and ISGA, pruritus scores, disease-free survival, and local tolerability. Both treatments were effective and well tolerated; fluticasone produced faster short-term improvement, while crisaborole showed a trend toward fewer relapses and similar overall safety in this pediatric population.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 12 Apr 2026
- Start date
- 1 Feb 2024
- Primary completion date
- 1 Dec 2024
- Lead sponsor
- Noura Abdelmoneim Mohammed Elseessy
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07537751
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 1 Feb 2024 to the primary completion date, 1 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of systemic corticosteroids, nonsteroidal systemic immunosuppressants (e.g., cyclosporine, methotrexate), or phototherapy within 4 weeks before baseline.
- Use of topical corticosteroids, transdermal corticosteroids, topical antibiotics, or any medicated topical agent within 1 week before baseline.
Other illness
- Significant medical condition requiring systemic medication (e.g., cancer).
- Current clinical diagnosis of bacterial skin infection (such as abscess or impetigo).
Other
- Severe atopic dermatitis (objective SCORAD \> 40).
Who the study is looking for
- Children of either sex aged 1 to 12 years.
- Clinical diagnosis of atopic dermatitis based on Hanifin and Rajka criteria.
- Mild to moderate disease with objective SCORAD up to 40.
- Investigator's Static Global Assessment (ISGA) score of 2 (mild) or 3 (moderate) at baseline.
Age in the registry: 1 year to 12 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine, Kafr Elsheikh University Coordinator of this site? Confirm its status | Kafr ash Shaykh | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.